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Abstract Background: Currently available over-the-
counter cough remedies historically have been criticized
for lack of scientific evidence supporting their efficacy.
Although the first-generation antihistamine diphenhy-
dramine is classified as an antitussive by the United States
Food and Drug Administration, to the authors’ knowledge
it has never been shown to inhibit cough reflex sensitivity
in subjects with pathological cough. Objective: To evaluate
the effect of diphenhydramine on cough reflex sensitivity.
Setting: Montefiore Medical Center, an academic medical
center in New York City. Methods: Twenty two subjects
with acute viral upper respiratory tract infection (common
cold) underwent cough reflex sensitivity measurement
employing capsaicin challenge on 3 separate days, 2 h
after ingesting single doses of study drug (to coincide with
peak blood concentrations), administered in randomized,
double-blind manner: a multicomponent syrup containing
diphenhydramine (25 mg), phenylephrine (10 mg), in a
natural cocoa formulation; dextromethorphan (30 mg)
syrup; and, placebo syrup. The standard endpoint of
cough challenge was used: concentration of capsaicin
inducing C5 coughs (C5). Main outcome measure: Effect
on cough reflex sensitivity (C5). Results: A significant
difference (p = 0.0024) was established among groups,
with pairwise analysis revealing a significant increase in
mean log C5 (0.4 ± 0.55 (SD); p\ 0.01) for the
diphenhydramine-containing medication versus placebo,
but not for dextromethorphan versus placebo. Conclu-
sions: Our results provide the initial evidence of the
ability of diphenhydramine to inhibit cough reflex sensi-
tivity in subjects with acute pathological cough. Timing
of cough reflex sensitivity measurement may not have
allowed demonstration of maximal antitussive effect of
dextromethorphan.
Keywords Antihistamine  Common cold  Cough 
Cough reflex  Diphenhydramine
Impact of findings on practice
• Over-the-counter (OTC) cough and cold medications
have long been criticized for lack of evidence sup-
porting their efficacy. This study demonstrates that
diphenhydramine indeed inhibits cough reflex
sensitivity.
• Diphenhydramine, a commonly-used first-generation
antihistamine in the US, is rightfully also classified as
an antitussive (cough suppressant) in the United States
Food and Drug Administration (FDA) OTC monograph.
ClinicalTrials.gov identifier: NCT 02062710.
This study was presented in abstract form at the European Respiratory
Society Annual Congress, September 8, 2014, Munich, Germany.
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Introduction
Cough is the most common complaint for which patients in
the United States seek medical attention [1]. Although
billions of dollars are spent annually on non-prescription,
OTC cough preparations, scant evidence exists supporting
the efficacy of these drugs as antitussives [2]. Three non-
narcotic oral agents are listed as antitussives in the United
States Food and Drug Administration (FDA) Final Mono-
graph for OTC Antitussive Drug Products: chlophedianol
[3], dextromethorphan [3], and the first-generation H1-an-
tihistamine, diphenhydramine [4]. Chlophedianol was first
introduced as an antitussive in Germany in the 1950s, but
very little published literature supports its efficacy [2].
Dextromethorphan, also available since the 1950s, is the
most commonly used OTC antitussive in the United States
and many other areas of the world. Although published
studies exist demonstrating the ability of dextromethorphan
to inhibit experimentally induced cough in healthy volun-
teers and to diminish pathological cough, most of these
investigations are decades old and lack the more robust
objective and subjective end points employed in current
antitussive trials [2]. Diphenhydramine has been shown to
inhibit citric acid-induced cough in healthy volunteers [5],
as well as to diminish pathological chronic cough relative
to placebo [6]. Furthermore, the guidelines of the American
College of Chest Physicians (ACCP) recommend the
combination of a first-generation H1-antihistamine and a
decongestant as the treatment of choice for chronic cough
due to upper airway cough syndrome (formerly known as
postnasal drip syndrome) and acute cough due to the
common cold [7], though this recommendation is based
largely on a vast body of clinical experience and expert
opinion, in the absence of adequately powered, prospec-
tive, randomized, controlled clinical trials [8].
Acute cough due to viral upper respiratory tract infec-
tion (URI; common cold) accounts for the majority of the
approximately 27 million cough-related health care provi-
der office visits annually in the United States [1], as well as
the significant cost of OTC products purchased to suppress
troublesome cough. Yet, to the authors’ knowledge, none
of the three FDA-approved OTC antitussive products
(chlophedianol, dextromethorphan, and diphenhydramine)
has ever been shown to inhibit experimentally induced
cough in subjects with acute cough due to URI.
Capsaicin, the pungent extract of red peppers, has been
shown in over three decades of clinical experience, to in-
duce cough in a safe, dose-dependent and reproducible
manner [9]. Thus, capsaicin cough challenge testing has
become an important tool in clinical research, allowing for
the accurate measurement of the effect of a pharmaco-
logical intervention on the sensitivity of the cough reflex
[9, 10]. The standard end point measured in capsaicin
cough challenge testing is the concentration of capsaicin
inducing 5 or more coughs (C5). In healthy volunteers, this
end point has been demonstrated to be highly reproducible,
in the short-term (20 min to 14 days) and long term
(months to years) [9]. Recently, it has been demonstrated
that cough reflex sensitivity, though transiently enhanced
during acute URI, remains stable in the first week of illness
[11]. Thus, in a clinical trial, any changes in cough reflex
sensitivity observed during this period may be attributed to
the pharmacological intervention being studied, rather than
to spontaneous variation in cough reflex sensitivity [11].
Aim of the Study
To evaluate the effect of a diphenhydramine-containing,
multicomponent syrup, compared with a dextromethor-
phan-containing syrup and placebo, on cough reflex sen-
sitivity in otherwise healthy subjects with acute URI.
Ethical approval
The study protocol was approved by the Institutional Re-
view Board of Montefiore Medical Center, Bronx, NY.
Methods
Otherwise healthy adult nonsmokers with the onset of
symptoms consistent with acute viral upper respiratory
tract infection (URI) within the previous 72 h were re-
cruited and enrolled after providing informed consent. The
study protocol was approved by the Institutional Review
Board of Montefiore Medical Center, Bronx, NY. Subjects
did not have a history of asthma or other pulmonary dis-
ease, nor history or symptoms suggestive of gastroe-
sophageal reflux disease. Subjects presenting with
symptoms suggestive of influenza, such as high fever,
myalgias, or severe illness, were excluded. Individuals with
URI who had taken any cough/cold medicines for their
illness were excluded, as were those currently receiving
any medication known to affect cough reflex sensitivity, or
who had received any such medication within a time frame
that would leave the possibility of a lingering effect of a
previously-ingested medication on the sensitivity of the
cough reflex.
Upon enrollment, subjects were randomized to receive
each of the three study formulations within a 3–5 days
period, in random order, 2 h prior to capsaicin challenge
testing, in a double-blind fashion. The study drugs con-
sisted of: diphenhydramine (25 mg) and phenylephrine
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(10 mg) in a natural cocoa formulation (Dr. Cocoa, Infirst
Healthcare, London, UK); dextromethorphan (30 mg)
syrup with licorice and sugar water among inactive ingre-
dients (Father John’s Medicine, Oakhurst Co., Levittown,
NY, USA); and, a solution of dextrose in water. A post-
ingestion period of 2 h was chosen to coincide with near-
peak blood concentrations of diphenhydramine [12] and
dextromethorphan [2, 13]. Study drugs were prepared as
20 ml liquid doses in opaque bottles that each subject was
instructed to drink, without commenting on the taste or
smell of the liquid. The investigators therefore were una-
ware of the appearance, smell, and other characteristics of
the study drugs administered.
Capsaicin cough challenge was performed as previously
described [9]. Briefly, subjects inhaled single, vital-ca-
pacity breaths of ascending, doubling concentrations (range
0.49–1000 lM) of aerosolized capsaicin solution, admin-
istered via a compressed air-driven nebulizer controlled by
a dosimeter, with 1-min intervals between inhalations, until
5 or more coughs resulted in the 15 s following an in-
halation. Placebo saline breaths were randomly inter-
spersed between capsaicin doses to increase challenge
blindness. The end point of capsaicin challenge testing is
the concentration of capsaicin inducing 5 or more coughs
(C5).
To evaluate the effect of each of the three study for-
mulations, differences in log C5 responses were analyzed
by 1-way ANOVA for dependent samples combined with
Tukey’s HSD test for pairwise comparisons.
Results
Twenty-two subjects [16 females; mean age 39.2 ±
13.3(SD) year] were recruited and completed the study.
Mean(± SD) log C5 values observed after administration
of each of the study drugs were: 0.57 ± 0.75 after placebo;
0.80 ± 0.83 after dextromethorphan; and, 0.97 ± 0.74
after the diphenhydramine-containing formulation (Fig. 1).
Differences in log C5 responses were analyzed by 1-way
ANOVA for dependent samples combined with Tukey’s
HSD test for pairwise comparisons. A significant differ-
ence (p = 0.0024) was established among the groups, with
pairwise analysis revealing a significant increase in mean
log C5 [0.4 ± 0.55(SD); p\ 0.01] for the diphenhy-
dramine-containing medication versus placebo, but not for
dextromethorphan versus placebo.
In terms of side effects, five subjects reported slight
drowsiness after ingesting the diphenhydramine-containing
formulation, as did one subject after placebo. Five subjects
reported side effects after ingesting the dextromethorphan
syrup: slight drowsiness in two subjects, slight nausea in
two subjects, and dry mouth in one subject.
Discussion
In the United States, the majority of OTC cough prepara-
tions contain dextromethorphan or diphenhydramine as the
pharmacologically active component. Significant criticism
has been directed at the OTC cough and cold market be-
cause of the lack of adequately performed clinical trials
demonstrating these agents to be effective antitussives
[2.7]. To the authors’ knowledge, this study represents the
first demonstration of the ability of diphenhydramine to
suppress cough reflex sensitivity in subjects with acute
URI. Furthermore, the diphenhydramine-containing for-
mulation proved a more effective antitussive than did
dextromethorphan, with both agents administered at stan-
dard antitussive doses. However, it should be noted that
cough reflex sensitivity was measured 2 h after study drug
administration, to coincide with near-peak blood concen-
trations of the agents under investigation. Such timing of
the cough challenge may not have allowed demonstration
of the maximal antitussive effect of dextromethorphan, as a
recent study of healthy volunteers found that maximal in-
hibition of capsaicin cough sensitivity by dextromethor-
phan was not observed until 6 h after oral administration
[14].
The multicomponent diphenhydramine-containing syrup
investigated in this study also contains the decongestant
phenylephrine at standard OTC dose as well as natural
cocoa flavoring. To our knowledge, phenylephrine has
never been suggested or demonstrated to have an antitus-
sive effect. Theobromine, a component of cocoa, has been
shown to have antitussive effect in healthy volunteers in
one previous study [15], however, the amount of theo-
bromine contained in one dose of the medication evaluated
herein is much smaller than that required for cough reflex
inhibition. Nevertheless, the thickness and cocoa flavor of
the diphenhydramine-containing formulation may be con-
tributing to the overall efficacy of the medication by cre-
ating a demulcent effect that has been proposed as an
important component of the perceived therapeutic effect of
cough syrups [16].
The three liquid formulations investigated were not able
to be perfectly blinded. The diphenhydramine-containing
syrup contained a natural cocoa flavoring; the dex-
tromethorphan-containing syrup contained licorice and
sugar water; and, the placebo was a dextrose solution.
However, we do not feel that the lack of perfect blinding
affected our results. Subjects knew that during the three
study days, they would be receiving two active medications
and a placebo. They were unaware, of course, of which
flavorings the active and placebo formulations would have.
Furthermore, this study did not measure subjective end
points. Had subjective end points been examined, espe-
cially soon after drug administration, then certainly the
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possibility of a demulcent effect of the various liquids may
have contributed to subject perception and experience [16].
However, our study measured only the objective end point
of cough reflex sensitivity to capsaicin, 2 h after study drug
administration, by which time any local throat sensations
and demulcent effects would have dissipated. It is note-
worthy that a recent study demonstrated that sweet sub-
stances can affect cough reflex sensitivity to capsaicin [17].
Thus, our placebo preparation was also sweetened so as to
present subjects with sweet liquids on each of the 3 days of
testing.
Conclusions
Although the first-generation antihistamine, diphenhy-
dramine, is classified as an antitussive by the FDA and is a
component of numerous OTC cough and cold preparations,
the present study, to our knowledge, contributes the initial
evidence demonstrating the ability of this agent to inhibit
cough reflex sensitivity in acute pathological cough. Fur-
ther clinical trials are needed to adequately evaluate this
and other OTC cough and cold products, so as to allow
physicians and consumers alike to make informed treat-
ment decisions based on proper scientific data.
Acknowledgments None.
Funding Infirst Healthcare Ltd., London, UK.
Conflicts of interest This study was supported by an unrestricted
grant from Infirst Healthcare Ltd. PVD has served as a consultant to,
and JB and WC-W are employees of, Infirst Healthcare Ltd. SD, AJ,
and YG have no conflicts of interest.
References
1. Hsiao C-J, Cherry DK, Beatty PC, Rechtsteiner E. National
ambulatory medical care survey: 2007 summary. National Health
Statistics Reports; No. 27. Hyatsville: National Center for Health
Statistics. 2010.
2. Dicpinigaitis PV, Morice AH, Birring SS, McGarvey L, Smith
JA, Canning BJ, et al. Antitussive drugs-past, present, and future.
Pharmacol Rev. 2014;66:468–512.
3. Department of Health and Human Services. Food and Drug
Administration. Cold, cough, allergy, bronchodilator, and anti-
asthmatic drug products for over-the-counter human use; final
monograph for OTC antitussive drug products. Fed Regist.
1987;52:30042–57.
4. Department of Health and Human Services. Food and Drug
Administration. Cold, cough, allergy, bronchodilator, and anti-
asthmatic drug products for over-the-counter human use;
amendment of final monograph for OTC antitussive drug prod-
ucts. Fed Regist. 1994;59:29172–4.
5. Packman EW, Ciccone PE, Wilson J, Masurat T. Antitussive
effects of diphenhydramine on the citric acid aerosol-induced
cough response in humans. Int J Clin Pharmacol Ther Toxicol.
1991;29:218–22.
6. Lilienfield LS, Rose JC, Princiotto JV. Antitussive activity of
diphenhydramine in chronic cough. Clin Pharmacol Ther. 1976;
19:421–5.
7. Irwin RS, Baumann MH, Bolser DC, Boulet L-P, Braman SS,
Brightling CE, et al. Diagnosis and management of cough: ACCP
evidence-based clinical practice guidelines. Chest. 2006;
129(Suppl 1):1S–292S.
8. Bjornsdottir I, Einarson TR, Gudmundsson LS, Einarsdottir RA.
Efficacy of diphenhydramine against cough in humans: a review.
Pharm World Sci. 2007;29:577–83.
9. Morice AH, Fontana GA, Belvisi MG, Birring SS, Chung KF,
Dicpinigaitis PV, et al. European Respiratory Society Task Force.
ERS guidelines on the assessment of cough. Eur Respir J.
2007;29:1256–76.
10. Dicpinigaitis PV. Review: effect of drugs on human cough reflex
sensitivity to inhaled capsaicin. Cough. 2012;8:10.
11. Dicpinigaitis PV, Tibb AS, Ramsey DL, Carr AN, Poore CL.
Stability of cough reflex sensitivity during viral upper respiratory
tract infection (common cold). Pulm Pharmacol Ther. 2014;28:
154–7.
12. Blyden GT, Greenblatt DJ, Scavone JM, Shader RI. Pharma-
cokinetics of diphenhydramine and a demethylated metabolite
following intravenous and oral administration. J Clin Pharmacol.
1986;26:529–33.
13. Capon DA, Bochner F, Kerry N, Mikus G, Danz C, Somogyi AA.
The influence of CYP2D6 polymorphism and quinidine on the
disposition and antitussive effect of dextromethorphan in hu-
mans. Clin Pharmacol Ther. 1996;60:295–307.
14. Faruqi S, Wright C, Thompson R, Morice A. A randomised
placebo controlled trial to evaluate the effects of butamirate and
dextromethorphan on capsaicin induced cough in healthy vol-
unteers. Br J Clin Pharmacol. 2014;. doi:10.1111/bcp.12458 Epub
ahead of print.
15. Usmani OS, Belvisi MG, Patel HJ, Crispino N, Birrell MA,
Korbonits M, et al. Theobromine inhibits sensory nerve activation
and cough. FASEB J. 2005;19:231–3.
16. Eccles R. Importance of placebo effect in cough clinical trials.
Lung. 2010;188(Suppl 1):S53–61.
17. Wise PM, Breslin PA, Dalton P. Sweet taste and menthol increase
cough reflex thresholds. Pulm Pharmacol Ther. 2012;25:236–41.










Fig. 1 Values for cough reflex sensitivity to capsaicin (log C5)
determined 2 h after ingestion of diphenhydramine (Dph), dex-
tromethorphan (Dx), and placebo in adult nonsmokers with acute viral
upper respiratory tract infection. Cough reflex sensitivity was
significantly inhibited (log C5 increased) after diphenhydramine
(p\ 0.01). Error bars represent SEM
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